Navigation Links
BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming,Clinical Conferences

JERUSALEM--(BUSINESS WIRE)--May 17, 2007 - BioLineRx Ltd. (TASE: BLRX), Israel's leading drug development company, announced today that abstracts containing data from its successfully completed phase I clinical trails of BL-1020, first in class GABA-enhanced antipsychotic for the treatment of schizophrenia, have been accepted for poster presentations at three leading scientific conferences. The data will be presented at the following conferences:

-- Society of Biological Psychiatry Annual Convention, May 17-19 (San Diego)

-- American Psychiatric Association Annual Meeting, May 19-24 (San Diego)

-- New Clinical Drug Evaluation Unit Annual (NCDEU) Meeting, June 11-14 (Boca Raton)

The abstract which has been selected for these poster presentations describes the results of a Phase I, randomized, placebo-controlled double blinded, single dose-escalation study to evaluate the safety and determine the pharmacokinetic profile of BL-1020, first in class GABA-enhanced antipsychotic for the treatment of schizophrenia.

"We are very pleased that these important data regarding the Phase I trials of BL-1020 are being presented at these three major psychiatric conferences. The Phase I studies support our product profile of a highly efficacious antipsychotic devoid of extrapyramidal symptoms or metabolic side effects," commented Morris Laster, chief executive officer of BioLineRx. "We continue to believe that the compound holds great promise for the treatment of schizophrenia, which currently poses an intractable medical problem for physicians and patients. We very much look forward to the initiation of the Phase II trial in the second quarter of 2007."

About BL-1020

BL-1020 is an orally available GABA enhanced antipsychotic clinical candidate for the treatment of schizophrenia. Data from preclinical and phase I studies demonstrated that the compound may retain the efficacy of currently
'"/>




Page: 1 2 3

Related medicine technology :

1. BioLineRx Presents Data From Successful Phase I Trial for BL-1020 in Schizophrenia at American Psychiatric Association Conference
2. BioLineRx Presents Data on BL-1040 at Cardiovascular Revascularization Therapies Conference Demonstrating Potential to Reduce Deterioration of Infarcted Heart Tissue and Maintain Functionality
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:12/24/2014)... SANTA BARBARA, Calif. , Dec. 23, 2014 ... the Junior Doctors, Association of Sierra Leone ... Sierra Leone for the treatment of local ... While a new dedicated Ebola care center was ... Ebola virus, the facility is not available for local Sierra ...
(Date:12/22/2014)... , Dec. 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), ... CytoSorb® blood purification technology to help fight deadly ... 28 countries worldwide, today announced the appointment of ... FACS, as its Senior Vice President of Clinical ... Dr. Di Russo is an accomplished ...
(Date:12/22/2014)... and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) has announced ... Market" report to their offering. ... focuses on the developments in the self-monitoring blood glucose ... Reimbursement analysis and the effects of competitive bidding have ... SMBG meters have been performed, based on the various ...
Breaking Medicine Technology:First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2
... Sheets: SIMH)  In a shrewd execution of its business ... with Keith Houlihan, Co-founder and President of Sanomedics ... signing of a letter of intent to acquire a ... platform in sleep apnea treatment services.  The targeted acquisition ...
... Dec. 12, 2011  Inovio Pharmaceuticals, Inc. (NYSE Amex: ... and infectious diseases, announced today that Dr. J. Joseph Kim, ... at the Oppenheimer 22nd Annual Healthcare Conference taking place December ... Inovio Presentation December 13 10:50 am ET ...
Cached Medicine Technology:Sanomedics Signs Letter of Intent to Acquire Large Sleep Disorder Service Based Operation 2Inovio Pharmaceuticals to Present at Oppenheimer Investor Conference 2Inovio Pharmaceuticals to Present at Oppenheimer Investor Conference 3
(Date:12/24/2014)... a famous bamboo flooring company offering bamboo flooring products ... its multiple layer bamboo panel board collection , and ... Bamboo panel is the product made from 100 percent ... features high quality selective bamboo and eco-friendly adhesives that ... consists of multiple layers of bamboo. , According to ...
(Date:12/24/2014)... -- The holidays can be a challenge for people who ... and drinks. "This is the season in which many ... Dr. David Dodick, chair of the American Migraine Foundation, said ... to think through food and beverage choices, to help reduce ... professor of neurology at the Mayo Clinic in Scottsdale, Ariz. ...
(Date:12/24/2014)... News) -- A new, injectable weight-loss drug has been ... The agency on Tuesday approved Saxenda (liraglutide) for adults ... and have at least one weight-related health condition, such ... cholesterol. Patients taking the drug, made by Novo ... regularly, the FDA noted. "Obesity is a public ...
(Date:12/24/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- Researchers say ... cells that develop into eggs and sperm. While ... this is the first time that these types of ... produced efficiently using human stem cells, according to the ... "The creation of primordial germ cells is one of ...
(Date:12/24/2014)... -- A lab technician with the U.S. Centers for ... the Ebola virus in an agency laboratory in Atlanta ... other lab workers are being checked for possible exposure, ... exposure occurred Monday when CDC scientists doing research on ... virus to another CDC lab in the same building, ...
Breaking Medicine News(10 mins):Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2Health News:Expert Offers Tips for Preventing Holiday Migraines 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:CDC Monitors Lab Worker for Possible Ebola Exposure 2
... MONDAY, Dec. 5 (HealthDay News) -- There,s been a large increase ... States since 2002, a trend that may help ease concerns about ... analyzed national data and found that the number of RNs aged ... fell to fewer than 110,000 by 1991 and remained low for ...
... University of Kentucky researchers recently received a $225,000 grant ... The grant gives the team $225,000 for the ... that could total $675,000. It is funded by the ... Rural Cancer Prevention Center. Published studies have shown ...
... By Serena Gordon HealthDay Reporter , MONDAY, Dec. ... with asthma is currently using a preventive medication, according to ... percent of kids during the late 1980s. Preventive ... up, and guidelines from the U.S. National Asthma Education and ...
... -- Teenagers with autism who also have epilepsy often ... The combination means that certain behaviors common among autistic ... of their faces -- could increase their risk for ... 14 percent of children with epilepsy, the rate jumps ...
... and non-obese children found that low vitamin D levels are ... risk factors for type 2 diabetes. This study was accepted ... Endocrinology & Metabolism (JCEM). High rates of vitamin ... studies have linked low vitamin D levels to cardiovascular disease ...
... , SATURDAY, Dec. 3 (HealthDay News) -- Seizures ... during menstruation or ovulation, researchers have found. ... at the University of California, Irvine, examined the trend ... among a group of women aged 19 to 50. ...
Cached Medicine News:Health News:Good News for Those Worried About U.S. Nursing Shortage 2Health News:University of Kentucky researchers awarded CDC grant to study cancer survival in Appalachia 2Health News:More Children Using Preventive Asthma Drugs: Study 2Health News:More Children Using Preventive Asthma Drugs: Study 3Health News:Low vitamin D levels may contribute to development of Type 2 diabetes 2Health News:Epileptic Seizures May Worsen During Menstrual Cycle 2
... Cutter has application in multiple open or ... resection, and/or creation of anastomoses and can ... buttressing materials such as bovine pericardium., ... a total of eight firings. Different cartridges ...
... in Open Procedures with Compact Endoscopic ... Compact-Flex45 No-Knife Articulating Linear Staplers is ... line for open surgical procedures. It ... blue cartridge, a thick-tissue green cartridge, ...
... ENDO CLIP MultApplier reusable clip applier is designed ... loading unit, each of which contains eight (8) ... shaft of the instrument is approximately 12.8" (32.5 ... and use through an appropriately sized Auto Suture ...
ENDO CLIP II ML, 10 mm Pistol Grip Single Use Clip Applier with Medium - Large Super Interlock Titanium Clips...
Medicine Products: